(Total Views: 354)
Posted On: 03/10/2017 9:36:24 AM
Post# of 22801
$SNGX
a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it will present results from its ricin toxin vaccine (RiVax™) development program at the Society of Toxicology 56th Annual Meeting. The meeting is being held on March 12-16, 2017 in Baltimore, MD and the poster will be available for viewing on Wednesday, March 15 from 9:30 a.m. to 12:45 p.m.
Poster Presentation Details:
-- Verification of Lethal Doses of Inhaled Ricin in Rhesus Macaques to
Support Vaccine Development presented by Dr. Gensheng Wang , Lovelace
Respiratory Research Institute and Dr. Thomas Measey , Soligenix Inc.
RiVax™ is the Company's proprietary vaccine candidate for the prevention of exposure to ricin toxin that utilizes a unique antigen that is completely devoid of the toxic activity of ricin. When formulated with Soligenix's proprietary vaccine heat stabilization technology, ThermoVax®, RiVax™ has demonstrated significantly enhanced thermostability and 100% protection in preclinical ricin aerosol challenge models.
The poster presentation focuses on the further optimization of the primate ricin challenge model that is important to facilitating future approval of RiVax™ under the US Food and Drug Administration ( FDA ) "Animal Rule". This work was funded by the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health , via Contract #HHSN272201400039C.
With the recent enactment of the 21st Century Cures Act in late 2016, FDA approval of RiVax™ has the potential to position the vaccine for a biodefense Priority Review Voucher (PRV), which may be utilized in future programs or sold. PRVs, under similar voucher programs such as with pediatric rare disease drug development, have sold for as much as $350 million .
About the Society of Toxicology Meeting
The Society of Toxicology (SOT) annual meeting is one of the largest annual meetings of toxicologists worldwide and brings together approximately 6500 toxicologists from over 50 countries. This year i
a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it will present results from its ricin toxin vaccine (RiVax™) development program at the Society of Toxicology 56th Annual Meeting. The meeting is being held on March 12-16, 2017 in Baltimore, MD and the poster will be available for viewing on Wednesday, March 15 from 9:30 a.m. to 12:45 p.m.
Poster Presentation Details:
-- Verification of Lethal Doses of Inhaled Ricin in Rhesus Macaques to
Support Vaccine Development presented by Dr. Gensheng Wang , Lovelace
Respiratory Research Institute and Dr. Thomas Measey , Soligenix Inc.
RiVax™ is the Company's proprietary vaccine candidate for the prevention of exposure to ricin toxin that utilizes a unique antigen that is completely devoid of the toxic activity of ricin. When formulated with Soligenix's proprietary vaccine heat stabilization technology, ThermoVax®, RiVax™ has demonstrated significantly enhanced thermostability and 100% protection in preclinical ricin aerosol challenge models.
The poster presentation focuses on the further optimization of the primate ricin challenge model that is important to facilitating future approval of RiVax™ under the US Food and Drug Administration ( FDA ) "Animal Rule". This work was funded by the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health , via Contract #HHSN272201400039C.
With the recent enactment of the 21st Century Cures Act in late 2016, FDA approval of RiVax™ has the potential to position the vaccine for a biodefense Priority Review Voucher (PRV), which may be utilized in future programs or sold. PRVs, under similar voucher programs such as with pediatric rare disease drug development, have sold for as much as $350 million .
About the Society of Toxicology Meeting
The Society of Toxicology (SOT) annual meeting is one of the largest annual meetings of toxicologists worldwide and brings together approximately 6500 toxicologists from over 50 countries. This year i
(0)
(0)
Nothing I state is intended to be a recommendation to buy or sell, opinion only. Readers are solely responsible for how they use the information.
Scroll down for more posts ▼
